BEGIN:VCALENDAR VERSION:2.0 PRODID:-//Bordeaux Institute of Oncology - ECPv6.17.3.1//NONSGML v1.0//EN CALSCALE:GREGORIAN METHOD:PUBLISH X-WR-CALNAME:Bordeaux Institute of Oncology X-ORIGINAL-URL:https://www.bricbordeaux.com/en/ X-WR-CALDESC:Events for Bordeaux Institute of Oncology REFRESH-INTERVAL;VALUE=DURATION:PT1H X-Robots-Tag:noindex X-PUBLISHED-TTL:PT1H BEGIN:VTIMEZONE TZID:Europe/Paris BEGIN:DAYLIGHT TZOFFSETFROM:+0100 TZOFFSETTO:+0200 TZNAME:CEST DTSTART:20230326T010000 END:DAYLIGHT BEGIN:STANDARD TZOFFSETFROM:+0200 TZOFFSETTO:+0100 TZNAME:CET DTSTART:20231029T010000 END:STANDARD BEGIN:DAYLIGHT TZOFFSETFROM:+0100 TZOFFSETTO:+0200 TZNAME:CEST DTSTART:20240331T010000 END:DAYLIGHT BEGIN:STANDARD TZOFFSETFROM:+0200 TZOFFSETTO:+0100 TZNAME:CET DTSTART:20241027T010000 END:STANDARD BEGIN:DAYLIGHT TZOFFSETFROM:+0100 TZOFFSETTO:+0200 TZNAME:CEST DTSTART:20250330T010000 END:DAYLIGHT BEGIN:STANDARD TZOFFSETFROM:+0200 TZOFFSETTO:+0100 TZNAME:CET DTSTART:20251026T010000 END:STANDARD END:VTIMEZONE BEGIN:VEVENT DTSTART;TZID=Europe/Paris:20241202T140000 DTEND;TZID=Europe/Paris:20241202T170000 DTSTAMP:20241128T154500Z CREATED:20241128T154500Z LAST-MODIFIED:20241128T154500Z UID:48261-1733148000-1733158800@www.bricbordeaux.com SUMMARY:Thesis defense Guillaume Herrault\, team 6 DESCRIPTION:Cancer Biology thesis defense : Guillaume Herrault\, Team 06 – MIRCADE\, Methods and Innovations for the Research in Pediatric Cancers. \nMonday\, December 2. Closed session \n“Nouvelles stratégies thérapeutiques dans le traitement du gliome infiltrant du tronc cérébral.” \nJury members:\nM. Nicolas LARMONIER\, Professeur des universités\, Université de Bordeaux\, Examinateur\nM. Eddy PASQUIER\, Directeur de recherche\, Aix Marseille Université\, Rapporteur\nMme Isabelle PELLIER\, Professeure des universités – praticienne hospitalière\, Université d’Angers\, Rapporteur\nM. Christophe GROSSET\, Directeur de recherche\, Université de Bordeaux\, Directeur de thèse URL:https://www.bricbordeaux.com/en/event/thesis-defense-guillaume-herrault-team-6/ CATEGORIES:Meetings,Scientific seminars,Thesis defenses ATTACH;FMTTYPE=image/jpeg:https://cdn-bricbordeaux.onlc.eu/wp-content/uploads/2024/11/soutenance-de-these-guillaume-herrault.jpg END:VEVENT BEGIN:VEVENT DTSTART;VALUE=DATE:20241209 DTEND;VALUE=DATE:20241211 DTSTAMP:20241118T164717Z CREATED:20240415T151530Z LAST-MODIFIED:20241118T164717Z UID:46419-1733702400-1733875199@www.bricbordeaux.com SUMMARY:"Neuro-oncology meets Neuroscience" Symposium DESCRIPTION:\n\n NEURO-ONCOLOGY MEETS NEUROSCIENCE\n \n\n  \n\n\n The Bordeaux Cancer Neuroscience (BCN) Initiative\n \n\nSymposium organized by Andreas Bikfalvi\, Ahmad Sharanek\, Thomas Mathivet\, Lucie Brisson\, Antonio Pagano Zottola équipe 1 de notre unité BRIC\, Valentin Nägerl (Institut interdisciplinaire de neurosciences\, IINS) and Thomas Daubon (Institut de Biochimie et Génétique Cellulaires\, IBGC) \n\nGlioblastoma (GB) is the most aggressive brain tumor characterized by high proliferation rate\, core necrosis\, microvascular proliferation and tumor infiltration. GB treatment consists in tumor resection by surgery and radiotherapy plus concomitant chemotherapy with temozolomide (Stupp et al\, 2005). However\, GB still remains incurable with a low median survival rate of approx. 15 months. This is due to resistance to treatment mainly caused by the presence of tumor cells that escape tumor resection by invading the normal brain parenchyma. Recent developments in immunotherapy did not succeed in overcoming this challenge. Unfortunately\, the mechanisms underlying GB development are still not fully understood and current model systems addressing these questions are not adequate\, impeding progress for the field. It has been shown that the tumor microenvironment (TME) in GB partially controls tumor growth and invasion\, and constitutes a therapeutic target (Bikfalvi et al\, 2022). A body of recent studies points to an important role of the normal neuronal brain environment in GB progression. \n\n\n This meeting brings people together from both\, the neuro-oncology and neuroscience communities to highlight these new developments occurring at the interface between neuro-oncology and the neurosciences.\n \n\n \n The conference is open to the general public with a half-day specifically dedicated to the Patients/Medical Staff/Researchers triptych (in French)\, organized by Sophie North (BRIC-BoRdeaux Institute of onCology).\n \n \n\n\n \n \nAll information and registrations : https://nomn2024.sciencesconf.org/ \nRegistration deadline: December 1st 2024 \nAbstract submission for poster presentation deadline : December 1st 2024 \nAbstract submission for flash poster presentation deadline : November 15th 2024 extended until Friday November 22 URL:https://www.bricbordeaux.com/en/event/neurooncology-meets-neuroscience-symposium/ LOCATION:Institut Broca\, 146 rue leo Saignat\, Bordeaux\, France CATEGORIES:Meetings,Scientific seminars ATTACH;FMTTYPE=image/jpeg:https://cdn-bricbordeaux.onlc.eu/wp-content/uploads/2024/04/symposium-neuro-oncologie-bordeaux-2024-12-910-1.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=Europe/Paris:20241210T143000 DTEND;TZID=Europe/Paris:20241210T153000 DTSTAMP:20241121T144417Z CREATED:20241114T114005Z LAST-MODIFIED:20241121T144417Z UID:48157-1733841000-1733844600@www.bricbordeaux.com SUMMARY:BRIC prestige seminar: Jean-Philippe Girard DESCRIPTION:Jean-Philippe Girard\, Directeur de Recherche INSERM \nCNRS Silver Medal 2013\,\nTeam leader “Biologie Vasculaire: Cellules endothéliales dans l’Immunité\, l’Inflammation et le Cancer”\nIPBS-CNRS (Institut de pharmacologie et de biologie structurale)\, Université de Toulouse\, Toulouse\, France. \nHigh endothelial venules (HEVs) : specialized blood vessels for lymphocyte entry in tumors during cancer immunotherapy \nConference in English.— \nTuesday\, December 10\, 2024\, 2:30 p.m. \nconference room BBS (Bordeaux\, Biologie Santé) 2 rue Dr Hoffmann Martinot – Site Carreire Université de Bordeaux \n  \nKeywords \nTumor microenvironnement\, Tumor-infiltrating lymphocytes\, Cancer immunotherapy \n  \nAbstract \nImmunotherapy\, a therapeutic strategy aimed at increasing the activity of the immune system\, has revolutionized cancer treatment over the past decade. A better understanding of how this therapeutic approach works\, and more particularly how killer lymphocytes access tumors during immunotherapy\, could improve the efficacy of the treatments. We recently discovered the essential role played in this process by specialized blood vessels known as tumor-associated high endothelial venules (TA-HEVs) (Asrir* et al. Cancer Cell 2022). TA-HEVs share important phenotypic and functional characteristics with HEVs in lymph nodes and other lymphoid organs (Moussion and Girard\, Nature 2011 ; Girard et al\, Nature Rev Immunol 2012). For the first time\, we were able to film the lymphocytes infiltrating TA-HEV walls to enter the tumors. We found that increasing the proportion of TA-HEVs in a tumor improves the infiltration of stem-like CD8+ T cells\, the efficacy of the immunotherapy and leads to the eradication of the tumors. Finally\, we showed that the likelihood of recovery of metastatic melanoma patients treated with anti-PD-1 plus anti-CTLA-4 immunotherapy is increased when a large number of TA-HEVs are present in tumors. Together our results suggest that increasing the density of TA-HEVs in human tumors could increase lymphocyte infiltration\, making immunotherapy effective in a greater number of patients. \n \nReferences \nAsrir\, A.*\, Tardiveau; C.*\, Coudert\, J.*\, Laffont\, R.*\, Blanchard\, L.*\, Bellard\, E.\, Veerman\, K.\, Bettini\, S.\, Lafouresse\, F.\, Vina\, E.\, Tarroux\, D.\, Roy\, S.\, Girault\, I.\, Molinaro\, I.\, Martins\, F.\, Scoazec\, J.Y.\, Ortega\, N.\, Robert\, C. and Girard\, J.P. (2022) Tumor-associated HEVs mediate lymphocyte entry into tumors and predict response to PD-1 plus CTLA-4 combination immunotherapy. Cancer Cell\, 40:318-334 (article sélectionné dans ‘Best of Cancer Cell 2022’\, ‘Highly cited article’ du Web of Science; 157 citations dans Google Scholar). \nGirard\, J.P.\, Moussion\, C.\, and Forster\, R. (2012). HEVs\, lymphatics and homeostatic immune cell trafficking in lymph nodes. Nat Rev Immunol 12\, 762-773. \nMoussion\, C.\, and Girard\, J.P. (2011). Dendritic cells control lymphocyte entry to lymph nodes through high endothelial venules. Nature 479\, 542-546. \n  \nBiosketch \nJean-Philippe Girard (PhD) currently holds a position of Senior Research Director at INSERM (French NIH) at IPBS-CNRS\, a large Research Center from the CNRS and the University of Toulouse (France). He received his Ph.D. in Molecular Biology from the University of Toulouse and did his postdoctoral training in Immunology and Vascular Biology at Harvard Medical School (USA) with Pr Tim Springer. Jean-Philippe Girard’s research focuses on the role of high endothelial venules (HEVs) and interleukin-33 (IL-33) in immunity\, inflammation and cancer. He discovered the alarmin cytokine IL-33 as a nuclear factor of HEV (NF-HEV). HEV blood vessels are portals of entry for lymphocytes into lymphoid organs (Moussion and Girard\, Nature 2011; Girard et al\, Nature Rev Immunol 2012). He showed that blood vessels with HEV characteristics designated tumor-associated HEVs are the main sites of lymphocyte entry into tumors\, and are associated with response to immune checkpoint blockade (Asrir* et al Cancer Cell 2022). Dr. Girard is a Highly Cited Researcher in Immunology according to the Web of Science (HCR Index 2023). He received several Scientific Prizes for his work\, including the CNRS Silver Medal (2103)\, and Prizes from the National Academy of Sciences (2012)\, the National Academy of Medecine (2013)\, ‘Fondation pour la Recherche Médicale’ (2016)\, ‘Fondation de France’ (2018) and ‘Fondation ARC’ (2024). \nJean-Philippe Girard is invited by Team 9 Sarcotarget to sit on the jury for Florent Peyraud’s thesis defense on the same day. URL:https://www.bricbordeaux.com/en/event/invited-seminar-jean-philippe-girard/ LOCATION:Salle de conférence BBS (Bordeaux Biologie Santé)\, 2 rue Dr Hoffmann Martinot\, Bordeaux CATEGORIES:Meetings,Scientific seminars ATTACH;FMTTYPE=image/jpeg:https://cdn-bricbordeaux.onlc.eu/wp-content/uploads/2024/11/prestige-seminar-jean-philippe-girard.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=Europe/Paris:20241213T140000 DTEND;TZID=Europe/Paris:20241213T170000 DTSTAMP:20241212T140913Z CREATED:20241203T153913Z LAST-MODIFIED:20241212T140913Z UID:48321-1734098400-1734109200@www.bricbordeaux.com SUMMARY:Thesis defense Clément Marcelin\, team 4 DESCRIPTION:Clément Marcelin\, Team 04 – Helicobacter-associated digestive cancers\, cancer stem cells and therapeutic strategies \nThesis director Nicolas Grenier \nPhD specialization: Bioimaging \nTitle : Combinaison de Modèles Expérimentaux et Cliniques pour l’Évaluation de la Thermométrie IRM \nSalle broussin Delorme and visio\nCHU Bordeaux Pellegrin\, Service d’imagerie médicale. \nFriday\, December 13\, 2pm \nJury members: \n\nPr. Vania Tacher\, Hopital Henri-Mondor\, Créteil\, rapporteur\nPr. Julien Frandon\, CHU Nîmes\, rapporteur\nPr. Nicolas Grenier\, Directeur de thèse\nPr. Hélène Vernhet-Kovacsik\, Hôpital Arnaud de Villeneuve\, Montpellier\nDr Eva Jambon\, CHU Bordeaux\n\nNotice of thesis defense at this link. URL:https://www.bricbordeaux.com/en/event/thesis-defense-clement-marcelin-team-4/ CATEGORIES:Meetings,Scientific seminars,Thesis defenses ATTACH;FMTTYPE=image/jpeg:https://cdn-bricbordeaux.onlc.eu/wp-content/uploads/2024/12/soutenance-de-these-clement-marcelin-team-4.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=Europe/Paris:20241216T123000 DTEND;TZID=Europe/Paris:20241216T170000 DTSTAMP:20241213T111802Z CREATED:20241213T111802Z LAST-MODIFIED:20241213T111802Z UID:48446-1734352200-1734368400@www.bricbordeaux.com SUMMARY:Mariella Spalato-Ceruso thesis defense - team 9 BRIC DESCRIPTION:thesis defense Dr Mariella Spalato-Ceruso\, team 9 Sarcotarget \nPhD specialization: Cell Biology and Pathophysiology \nTitle : Profil génomique et immunologique des sarcomes métastatiques des tissus mous. \nMonday\, December 16 – 12:30 p.m. \nMeeting Room 7th floor\nInstitut Bergonié Building G\n229 Cours de l’Argonne 33000 Bordeaux \nNotice of defense at this link URL:https://www.bricbordeaux.com/en/event/mariella-spalato-ceruso-thesis-defense-team-9-bric/ LOCATION:Institut Bergonié\, 229 Cours de l'Argonne\, Bordeaux\, 33076\, France CATEGORIES:Meetings,Scientific seminars,Thesis defenses ATTACH;FMTTYPE=image/jpeg:https://cdn-bricbordeaux.onlc.eu/wp-content/uploads/2024/12/soutenance-de-these-mariella-spalato-team-9.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=Europe/Paris:20241220T100000 DTEND;TZID=Europe/Paris:20241220T140000 DTSTAMP:20241212T101800Z CREATED:20241212T101800Z LAST-MODIFIED:20241212T101800Z UID:48363-1734688800-1734703200@www.bricbordeaux.com SUMMARY:Camille Tocqueville thesis defense - MIRCADE team - BRIC DESCRIPTION:Camille Tocqueville‘s thesis defense\, team 06 – MIRCADE (Methods and Innovations for Childhood Cancer Research). \nThesis director Philippe VESCHAMBRE \nPhD specialty: Cancer biology. \n“Implication de la Striatin3 dans la régulation des voies Wnt et Hippo dans le carcinome hépatocellulaire et son rôle de suppresseur de tumeur dans l’hépatoblastome” \nFriday\, December 20\, 10 a.m. \nAmphi BBS\, 2 rue du Dr Hoffmann Martinot\, Bordeaux \nNotice of thesis defense at this link URL:https://www.bricbordeaux.com/en/event/camille-tocqueville-thesis-defense-mircade-team-bric/ LOCATION:Salle de conférence BBS (Bordeaux Biologie Santé)\, 2 rue Dr Hoffmann Martinot\, Bordeaux CATEGORIES:Meetings,Scientific seminars,Thesis defenses ATTACH;FMTTYPE=image/jpeg:https://cdn-bricbordeaux.onlc.eu/wp-content/uploads/2024/12/soutenance-de-these-camille-tocqueville-bric.jpg END:VEVENT END:VCALENDAR